The mechanism of action of retigabine (ezogabine), a first-in-class K + channel opener for the treatment of epilepsy

Epilepsia

Volumn 53, Issue 3, 2012, Pages 412-424

  Gunthorpe, Martin J ^a   Large, Charles H ^b   Sankar, Raman ^c  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GSK   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticonvulsant; Antiepileptic; Antiepileptic drugs; KCNQ; M current

Indexed keywords

10,10 BIS(4 PYRIDINYLMETHYL) 9(10H) ANTHRACENONE; 4 AMINOBUTYRIC ACID RECEPTOR; BICUCULLINE; CALCIUM CHANNEL; GLUTAMATE RECEPTOR; LINOPIRDINE; POTASSIUM CHANNEL KCNQ2; POTASSIUM CHANNEL KCNQ3; POTASSIUM CHANNEL KCNQ4; POTASSIUM CHANNEL KCNQ5; RADIOLIGAND; RETIGABINE; SODIUM CHANNEL;

BINDING ASSAY; BRAIN TISSUE; CHANNEL GATING; DRUG EFFECT; DRUG MECHANISM; ELECTROPHYSIOLOGY; EPILEPSY; HUMAN; HYPERPOLARIZATION; MEMBRANE STEADY POTENTIAL; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTICONVULSANTS; CARBAMATES; EPILEPSY; HUMANS; KCNQ POTASSIUM CHANNELS; PHENYLENEDIAMINES; RATS; TREATMENT OUTCOME;

EID: 84857646270     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2011.03365.x     Document Type: Review

References (61)

1. Alexander SP, Mathie A, Peters JA,. (2008) Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Armand V, Rundfeldt C, Heinemann U,. (1999) Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 359: 33-39. (Pubitemid 29142567)
3. Armand V, Rundfeldt C, Heinemann U,. (2000) Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 41: 28-33. (Pubitemid 30036851)
4. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, Steinlein OK,. (1998) A potassium channel mutation in neonatal human epilepsy. Science 279: 403-406. (Pubitemid 28063379)
5. Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, Nohria V, Mansbach H,; RESTORE 2 Study Group. (2010) Efficacy and safety of ezogabine (retigabine) in refractory partial epilepsy. Neurology 75: 1817-1824.
6. Brown DA, Passmore GM,. (2009) Neural KCNQ (Kv7) channels. Br J Pharmacol 156: 1185-1195.
7. Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, Leach RJ, Leppert M,. (1998) A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 18: 53-55. (Pubitemid 28027879)
8. Chung HJ, Jan YN, Jan LY,. (2006) Polarized axonal surface expression of neuronal KCNQ channels is mediated by multiple signals in the KCNQ2 and KCNQ3 C-terminal domains. Proc Natl Acad Sci USA 103: 8870-8875. (Pubitemid 43878110)
9. Devaux JJ, Kleopa KA, Cooper EC, Scherer SS,. (2004) KCNQ2 is a nodal K+ channel. J Neurosci 24: 1236-1244.
10. Dost R, Rundfeldt C,. (2000) The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca ++ and low Mg++ model in the hippocampal slice preparation. Epilepsy Res 38: 53-66. (Pubitemid 30055316)
11. French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S, Mansbach H, Nohria V,; On behalf of the RESTORE 1/Study 301 Investigators. (2011) Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76: 1555-1563.
12. Gribkoff VK,. (2003) The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 7: 737-748. (Pubitemid 37541260)
13. Gu N, Vervaeke K, Hu H, Storm JF,. (2005) Kv7/KCNQ/M and HCN/h, but not KCa2/SK channels, contribute to the somatic medium after-hyperpolarization and excitability control in CA1 hippocampal pyramidal cells. J Physiol 566: 689-715. (Pubitemid 41122655)
14. Hetka R, Rundfeldt C, Heinemann U, Schmitz D,. (1999) Retigabine strongly reduces repetitive firing in rat entorhinal cortex. Eur J Pharmacol 386: 165-171. (Pubitemid 30017707)
15. Jentsch TJ,. (2000) Neuronal KCNQ potassium channels: physiology and role in disease. Nat Rev Neurosci 1: 21-30.
16. Kapetanovic IM, Yonekawa WD, Kupferberg HJ,. (1995) The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro. Epilepsy Res 22: 167-173.
17. Kharkovets T, Hardelin JP, Safieddine S, Schweizer M, El-Amraoui A, Petit C, Jentsch TJ,. (2000) KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. Proc Natl Acad Sci USA 97: 4333-4338. (Pubitemid 30226133)
18. Kharkovets T, Dedek K, Maier H, Schweizer M, Khimich D, Nouvian R, Vardanyan V, Leuwer R, Moser T, Jentsch TJ,. (2006) Mice with altered KCNQ4 K+ channels implicate sensory outer hair cells in human progressive deafness. EMBO J 25: 642-652. (Pubitemid 43237670)
19. Kwan P, Brodie MJ,. (2000) Early identification of refractory epilepsy. N Engl J Med 342: 314-319. (Pubitemid 30075244)
20. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen HW, Mathern G, Moshe SL, Perucca E, Wiebe S, French J,. (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51: 1069-1077.
21. Lange W, Geissendorfer J, Schenzer A, Grotzinger J, Seebohm G, Friedrich T, Schwake M,. (2009) Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol 75: 272-280.
22. Large CH, Sokal DM, Nehlig A, Gunthorpe MJ, Sankar R, Crean CS, VanLandingham KE, White S,. (2012) The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: Implications for clinical use. Epilepsia 53: 425-436.
23. Lerche C, Scherer CR, Seebohm G, Derst C, Wei AD, Busch AE, Steinmeyer K,. (2000) Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity. J Biol Chem 275: 22395-22400. (Pubitemid 30621826)
24. Lerche C, Bruhova I, Lerche H, Steinmeyer K, Wei AD, Strutz-Seebohm N, Lang F, Busch AE, Zhorov BS, Seebohm G,. (2007) Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter. Mol Pharmacol 71: 1503-1511. (Pubitemid 47010903)
25. Luszczki JJ, Wu JZ, Raszewski G, Czuczwar SJ,. (2009) Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol 379: 163-179.
26. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA,. (2000) Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 58: 253-262. (Pubitemid 30497468)
27. Maljevic S, Wuttke TV, Lerche H,. (2008) Nervous system KV7 disorders: breakdown of a subthreshold brake. J Physiol 586: 1791-1801. (Pubitemid 351997508)
28. Mazarati A, Wu J, Shin D, Kwon YS, Sankar R,. (2008) Antiepileptogenic and antiictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study. Epilepsia 49: 1777-1786.
29. Meldrum BS, Rogawski MA,. (2007) Molecular targets for antiepileptic drug development. Neurotherapeutics 4: 18-61. (Pubitemid 46107329)
30. Otto JF, Kimball MM, Wilcox KS,. (2002) Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. Mol Pharmacol 61: 921-927. (Pubitemid 34273173)
31. Pan Z, Kao T, Horvath Z, Lemos J, Sul JY, Cranstoun SD, Bennett V, Scherer SS, Cooper EC,. (2006) A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon. J Neurosci 26: 2599-2613. (Pubitemid 43357843)
32. A receptors involved in pain sensation. BMC Pharmacol 8 (Suppl. 1): A14.
33. Porter RJ, Nohria V, Rundfeldt C,. (2007) Retigabine. Neurotherapeutics 4: 149-154. (Pubitemid 46107330)
34. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, Kutscher B, Loscher W, Honack D, White HS, Wolf HH,. (1996) D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 23: 211-223. (Pubitemid 26176549)
35. Rundfeldt C,. (1997) The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur J Pharmacol 336: 243-249. (Pubitemid 27464871)
36. Rundfeldt C,. (1999) Characterization of the K+ channel opening effect of the anticonvulsant retigabine in PC12 cells. Epilepsy Res 35: 99-107. (Pubitemid 29243042)
37. Rundfeldt C, Netzer R,. (2000a) Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 50: 1063-1070. (Pubitemid 32002997)
38. Rundfeldt C, Netzer R,. (2000b) The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 282: 73-76. (Pubitemid 30129172)
39. Sankar R, Wu J, Shin D, Mazarati A,. (2008) Retigabine inhibits rapid kindling epileptogenesis in rats through the activation of Kv7.2/7.3 channels. 8th European Congress on Epileptology, Berlin, Germany, September 21-25, 2008. Abstract T153.
40. Schenzer A, Friedrich T, Pusch M, Saftig P, Jentsch TJ, Grotzinger J, Schwake M,. (2005) Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci 25: 5051-5060. (Pubitemid 40712849)
41. Seebohm G, Chen J, Strutz N, Culberson C, Lerche C, Sanguinetti MC,. (2003) Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol Pharmacol 64: 70-77. (Pubitemid 36759819)
42. Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M,. (2000) Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 52: 557-594.
43. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV, McHarg ML, Gagnon D, Rosales TO, Peiffer A, Anderson VE, Leppert M,. (1998) A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 18: 25-29. (Pubitemid 28027874)
44. Smith MD, Adams AC, Saunders GW, White HS, Wilcox KS,. (2007) Phenytoin- and carbamazepine-resistant spontaneous bursting in rat entorhinal cortex is blocked by retigabine in vitro. Epilepsy Res 74: 97-106. (Pubitemid 46654739)
45. Storm JF,. (1989) An after-hyperpolarization of medium duration in rat hippocampal pyramidal cells. J Physiol 409: 171-190. (Pubitemid 19052978)
46. Straub H, Kohling R, Hohling J, Rundfeldt C, Tuxhorn I, Ebner A, Wolf P, Pannek H, Speckmann E,. (2001) Effects of retigabine on rhythmic synchronous activity of human neocortical slices. Epilepsy Res 44: 155-165. (Pubitemid 32452225)
47. Surti TS, Jan LY,. (2005) A potassium channel, the M-channel, as a therapeutic target. Curr Opin Investig Drugs 6: 704-711. (Pubitemid 40904041)
48. Swartz KJ,. (2004) Towards a structural view of gating in potassium channels. Nat Rev Neurosci 5: 905-916. (Pubitemid 39593354)
49. Tatulian L, Brown DA,. (2003) Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J Physiol 549: 57-63. (Pubitemid 36626397)
50. Tatulian L, Delmas P, Abogadie FC, Brown DA,. (2001) Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 21: 5535-5545. (Pubitemid 32692152)
51. Tober C, Rostock A, Rundfeldt C, Bartsch R,. (1996) D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 303: 163-169. (Pubitemid 26200668)
52. Tompson DJ, Crean CS, Reeve R, Berry S,. Exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures. J Clin Pharmacol In press.
53. van Rijn CM, Willems-van Bree E,. (2003) Synergy between retigabine and GABA in modulating the convulsant site of the GABAA receptor complex. Eur J Pharmacol 464: 95-100. (Pubitemid 36293726)
54. van Rijn CM, Willems-van Bree E,. (2004) A four-ligand hypercube model to quantify allosteric interactions within the GABAA receptor complex. Eur J Pharmacol 485: 43-51. (Pubitemid 38134396)
55. A receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr Opin Pharmacol 5: 47-52. (Pubitemid 40124534)
56. Watanabe H, Nagata E, Kosakai A, Nakamura M, Yokoyama M, Tanaka K, Sasai H,. (2000) Disruption of the epilepsy KCNQ2 gene results in neural hyperexcitability. J Neurochem 75: 28-33. (Pubitemid 30418165)
57. Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK,. (2000) Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 58: 591-600.
58. Wickenden AD, Zou A, Wagoner PK, Jegla T,. (2001) Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 132: 381-384. (Pubitemid 32142349)
59. Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H,. (2005) The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 67: 1009-1017. (Pubitemid 40410403)
60. Yeung SY, Lange W, Schwake M, Greenwood IA,. (2008) Expression profile and characterisation of a truncated KCNQ5 splice variant. Biochem Biophys Res Commun 371: 741-746.
61. Yue C, Yaari Y,. (2004) KCNQ/M channels control spike afterdepolarization and burst generation in hippocampal neurons. J Neurosci 24: 4614-4624. (Pubitemid 38656617)